The GPIIIA PlA2 polymorphism is associated with an increased risk of cardiovascular adverse events

BMC Cardiovascular Disorders

Volumn 10, Issue , 2010, Pages

  Galasso, Gennaro ^a   Santulli, Gaetano ^a   Piscione, Federico ^a   De Rosa, Roberta ^a   Trimarco, Valentina ^a   Piccolo, Raffaele ^a   Cassese, Salvatore ^a   Iaccarino, Guido ^a   Trimarco, Bruno ^a   Chiariello, Massimo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; GLYCOPROTEIN IIIA; PLATELET ANTIGEN 1; THROMBOCYTE ANTIGEN; UNCLASSIFIED DRUG; BETA3 INTEGRIN; VITRONECTIN RECEPTOR;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HEALTH CARE NEED; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERTENSION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; TRANSIENT ISCHEMIC ATTACK; AGED; ALLELE; CORONARY ARTERY THROMBOSIS; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PROGNOSIS; SURVIVAL;

AGED; ALLELES; ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTEGRIN ALPHAVBETA3; INTEGRIN BETA3; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 77956586039     PISSN: None     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/1471-2261-10-41     Document Type: Article

References (27)

1. Davi G, Patrono C. Platelet activation and atherothrombosis. The New England journal of medicine 2007, 357(24):2482-2494. 10.1056/NEJMra071014, 18077812.
2. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. The New England journal of medicine 1995, 332(23):1553-1559. 10.1056/NEJM199506083322306, 7739710.
3. Atherosclerosis T, . Vascular Biology Italian Study Group No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age. Circulation 2003, 107(8):1117-1122. 10.1161/01.CIR.0000051465.94572.D0, 12615788, Vascular Biology Italian Study Group.
4. Payrastre B, Missy K, Trumel C, Bodin S, Plantavid M, Chap H. The integrin alpha IIb/beta 3 in human platelet signal transduction. Biochemical pharmacology 2000, 60(8):1069-1074. 10.1016/S0006-2952(00)00417-2, 11007943.
5. Calvete JJ. On the structure and function of platelet integrin alpha IIb beta 3, the fibrinogen receptor. Proceedings of the Society for Experimental Biology and Medicine Society for Experimental Biology and Medicine (New York, NY 1995, 208(4):346-360.
6. Newman PJ, Derbes RS, Aster RH. The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. The Journal of clinical investigation 1989, 83(5):1778-1781. 10.1172/JCI114082, 303891, 2565345.
7. Michelson AD, Furman MI, Goldschmidt-Clermont P, Mascelli MA, Hendrix C, Coleman L, Hamlington J, Barnard MR, Kickler T, Christie DJ, et al. Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists. Circulation 2000, 101(9):1013-1018.
8. Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, Weiss JL, Gerstenblith G, Goldschmidt-Clermont PJ. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. The New England journal of medicine 1996, 334(17):1090-1094. 10.1056/NEJM199604253341703, 8598867.
9. Mikkelsson J, Perola M, Kauppila LI, Laippala P, Savolainen V, Pajarinen J, Penttila A, Karhunen PJ. The GPIIIa Pl(A) polymorphism in the progression of abdominal aortic atherosclerosis. Atherosclerosis 1999, 147(1):55-60. 10.1016/S0021-9150(99)00163-X, 10525125.
10. Bojesen SE, Juul K, Schnohr P, Tybjaerg-Hansen A, Nordestgaard BG. Platelet glycoprotein IIb/IIIa Pl(A2)/Pl(A2) homozygosity associated with risk of ischemic cardiovascular disease and myocardial infarction in young men: the Copenhagen City Heart Study. Journal of the American College of Cardiology 2003, 42(4):661-667. 10.1016/S0735-1097(03)00781-2, 12932598.
11. Zhu MM, Weedon J, Clark LT. Meta-analysis of the association of platelet glycoprotein IIIa PlA1/A2 polymorphism with myocardial infarction. The American journal of cardiology 2000, 86(9):1000-1005. A1008, 10.1016/S0002-9149(00)01136-X, 11053714.
12. Kullo IJ, Ding K. Mechanisms of disease: The genetic basis of coronary heart disease. Nature clinical practice 2007, 4(10):558-569. 10.1038/ncpcardio0982, 17893684.
13. De Luca N, Izzo R, Iaccarino G, Malini PL, Morisco C, Rozza F, Iovino GL, Rao MA, Bodenizza C, Lanni F, et al. The use of a telematic connection for the follow-up of hypertensive patients improves the cardiovascular prognosis. Journal of hypertension 2005, 23(7):1417-1423. 10.1097/01.hjh.0000173526.65555.55, 15942466.
14. Smith SC, Dove JT, Jacobs AK, Kennedy JW, Kereiakes D, Kern MJ, Kuntz RE, Popma JJ, Schaff HV, Williams DO, et al. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines)-executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions. Circulation 2001, 103(24):3019-3041.
15. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987, 76(1):142-154.
16. Ellis SG, Vandormael MG, Cowley MJ, DiSciascio G, Deligonul U, Topol EJ, Bulle TM. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. Circulation 1990, 82(4):1193-1202.
17. Adams H, Adams R, Del Zoppo G, Goldstein LB. Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update a scientific statement from the Stroke Council of the American Heart Association/American Stroke Association. Stroke; a journal of cerebral circulation 2005, 36(4):916-923.
18. Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke; a journal of cerebral circulation 24(1):35-41.
19. Easton JD, Albers GW, Caplan LR, Saver JL, Sherman DG. Discussion: Reconsideration of TIA terminology and definitions. Neurology 2004, 62(8 Suppl 6):S29-34.
20. Lanni F, Santulli G, Izzo R, Rubattu S, Zanda B, Volpe M, Iaccarino G, Trimarco B. The Pl(A1/A2) polymorphism of glycoprotein IIIa and cerebrovascular events in hypertension: increased risk of ischemic stroke in high-risk patients. Journal of hypertension 2007, 25(3):551-556. 10.1097/HJH.0b013e328013cd67, 17278970.
21. Piscione F, Iaccarino G, Galasso G, Cipolletta E, Rao MA, Brevetti G, Piccolo R, Trimarco B, Chiariello M. Effects of Ile164 polymorphism of beta2-adrenergic receptor gene on coronary artery disease. J Am Coll Cardiol 2008, 52(17):1381-1388. 10.1016/j.jacc.2008.07.034, 18940527.
22. Bojesen SE, Juul K, Schnohr P, Tybjaerg-Hansen A, Nordestgaard BG. Platelet glycoprotein IIb/IIIa Pl(A2)/Pl(A2) homozygosity associated with riqk of ischemic cardiOvascular disease and myocardial infarction in young men: the Copenhagen City Heart Study. J Am Coll of Cardiol 2003, 42(4):661-667.
23. Kastrati A, Schomig A, Seyfarth M, Koch W, Elezi S, Bottiger C, Mehilli J, Schomig K, von Beckerath N. PlA polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement. Circulation 1999, 99(8):1005-1010.
24. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. The New England journal of medicine 1989, 321(3):129-135. 10.1056/NEJM198907203210301, 2664509.
25. Ridker PM, Hennekens CH, Schmitz C, Stampfer MJ, Lindpaintner K. PIA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis. Lancet 1997, 349(9049):385-388. 10.1016/S0140-6736(97)80010-4, 9033464.
26. Goldschmidt-Clermont PJ, Roos CM, Cooke GE. Platelet PlA2 polymorphism and thromboembolic events: from inherited risk to pharmacogenetics. Journal of thrombosis and thrombolysis 1999, 8(2):89-103. 10.1023/A:1008954916972, 10436139.
27. Mikkelsson J, Perola M, Laippala P, Penttila A, Karhunen PJ. Glycoprotein IIIa Pl(A1/A2) polymorphism and sudden cardiac death. J Am Coll Cardiol 2000, 36(4):1317-1323. 10.1016/S0735-1097(00)00871-8, 11028489.